8-K: Apellis Pharmaceuticals Reports Strong 2024 Revenue Growth and Outlines Strategic Priorities

Apellis Pharmaceuticals announced preliminary 2024 U.S. net product revenues of $709 million, driven by strong sales of SYFOVRE and EMPAVELI, and outlined strategic priorities for continued growth.

Summary

• Apellis Pharmaceuticals reported preliminary unaudited U.S. net product revenues of $709 million for the full year 2024.
• SYFOVRE generated $611 million in U.S. net product revenues for the year, including $167 million in the fourth quarter.
• EMPAVELI contributed $98 million in U.S. net product revenues for the year, with $23 million in the fourth quarter.
• The company estimates over 510,000 SYFOVRE injections have been administered through December 2024.
• Apellis had approximately $410 million in cash and cash equivalents as of December 31, 2024.
• The company expects to submit a supplemental new drug application (sNDA) for EMPAVELI for C3G and primary IC-MPGN in early 2025, with a U.S. launch anticipated in the second half of 2025 if approved.
• Apellis plans to initiate Phase 3 studies of pegcetacoplan in two additional nephrology indications in the second half of 2025.
• The company is reducing its ex-U.S. footprint by approximately 40 employees to prioritize commercial efforts in the U.S.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with strong revenue growth, a solid cash position, and strategic expansion plans. The departure of the COO is a minor negative, but the overall tone is optimistic.

Positives

• The company reported strong preliminary full-year 2024 U.S. net product revenues of $709 million.
• SYFOVRE is the market-leading treatment for geographic atrophy (GA) with over 120% net sales growth year-over-year.
• Apellis has a strong cash position of approximately $410 million at the end of 2024.
• The company anticipates its cash and expected revenues will be sufficient to fund operations to profitability.
• The company is advancing its pipeline with a Phase 1b/2 study of APL-3007 + SYFOVRE expected in 2Q 2025.
• The company is expanding EMPAVELI's use into nephrology with planned sNDA submission and Phase 3 studies.

Negatives

• The reported revenue figures are preliminary and unaudited, subject to completion of financial closing procedures.
• The company is reducing its ex-U.S. footprint by approximately 40 employees.
• There is a risk of serious infections associated with EMPAVELI, requiring a restricted program under a REMS.

Risks

• The preliminary revenue figures are subject to change upon completion of financial closing procedures.
• There is a risk that the sNDA for EMPAVELI may not be approved by regulatory agencies.
• Clinical trial results may not be indicative of real-world outcomes.
• Market acceptance of new products may be slower than anticipated.
• The company faces risks related to serious infections caused by encapsulated bacteria with EMPAVELI use.
• There are risks associated with intravitreal injections of SYFOVRE, including endophthalmitis and retinal detachments.

Future Outlook

Apellis anticipates its cash, combined with expected product revenues, will be sufficient to fund its projected operating expenses and capital expenditures to profitability. The company plans to expand the use of EMPAVELI into nephrology and continue to grow SYFOVRE sales.

Management Comments

• Cedric Francois, M.D., Ph.D., stated that SYFOVRE is the market-leading treatment for GA, with more than 120% net sales growth year-over-year.
• Cedric Francois, M.D., Ph.D., said they are entering 2025 with strong momentum and look to build on this by unlocking the blockbuster potential of SYFOVRE and EMPAVELI.
• Cedric Francois, M.D., Ph.D., thanked Adam Townsend for his contributions to Apellis.
• Cedric Francois, M.D., Ph.D., noted David Acheson's impressive history of driving exceptional results.

Industry Context

The announcement highlights Apellis's strong position in the complement therapeutics market, particularly in the treatment of geographic atrophy and paroxysmal nocturnal hemoglobinuria. The company's focus on expanding into nephrology aligns with the growing interest in rare kidney disease treatments.

Comparison to Industry Standards

• Apellis's SYFOVRE is the first approved treatment for geographic atrophy, giving it a significant advantage over competitors in this space.
• The 120% year-over-year growth in SYFOVRE sales indicates strong market adoption, which is a positive sign compared to other new drug launches.
• The company's focus on expanding EMPAVELI into nephrology positions it to compete with companies like Alexion (now part of AstraZeneca) that have a strong presence in rare disease treatments.
• The cash position of $410 million is a good indicator of financial stability compared to other biotech companies of similar size.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and positive outlook.
• Employees may be affected by the reduction in the ex-U.S. workforce.
• Patients with geographic atrophy and PNH will benefit from the continued availability and potential expansion of SYFOVRE and EMPAVELI.
• Physicians will have access to new treatment options for rare kidney diseases.

Next Steps

• Submission of EMPAVELI sNDA for C3G and primary IC-MPGN in early 2025.
• U.S. launch of EMPAVELI for C3G and primary IC-MPGN anticipated in 2H 2025, if approved.
• Initiation of Phase 3 studies of pegcetacoplan in two additional nephrology indications in 2H 2025.
• Initiation of Phase 1b/2 multi-dose study of APL-3007 (siRNA) + SYFOVRE expected in 2Q 2025.

Key Dates

Keywords

SYFOVRE, EMPAVELI, pegcetacoplan, geographic atrophy, paroxysmal nocturnal hemoglobinuria, nephrology, revenue, clinical trials, sNDA, biopharmaceutical